Case Study: AstraZeneca Finds Success with a CSO Education Program

In 1998 AstraZeneca received FDA marketing clearance for PerioChipO, indicated for treating adult periodontitis. To build brand equity among the product's target of dentists,
periodontists and dental hygienists, AstraZeneca developed a CSO program that used educational programming, thought leader development, and third party advocacy.